To highlight this, it is important to mention that in a clinical trial, in which IFNγ was targeted via an anti-IFNγ monoclonal antibody, no therapeutic impacts were produced in a cohort of non-African-American SLE patients with lupus nephritis,21 probably due to the fact that ABCs/DN2 – which require IFNγ for their activation – are more marked in African-American patients. Here, IFNG is linked to systemic lupus erythematosus.